Established in 2001, Eddingpharm has always been dedicated to becoming China's leading supplier of patented drugs and branded medicines. With their effective operation cost management and expansion to lower-tier medical terminals, they bridge the gap between Chinese patients and global high quality medicines. Moreover, Eddingpharm continuously innovates and introduces abroad patented drugs to the China market, participates in international multi-center clinical trials, and strives to launch new drugs both in China and globally simultaneously, providing physicians with more treatment options. In the past few years, Eddingpharm has rapidly grown and strategically deployed resources in various fields, upgrading to an all-encompassing industry-chain entity from simply in-licensing R&D and commercialization. Today, Eddingpharm has nearly 1,000 professionals working in 30 provinces across the country, providing coverage for 19,000+ hospitals and 20,000+ pharmacies. They have formed strategic alliances with multinational pharmaceutical companies, specialty pharmaceutical companies, and leading R&D institutions, enriching their product portfolio through in-licensing of patented drugs, setting up joint ventures, acquiring exclusive distribution rights, and more. Their focused therapy areas now include anti-biology, oncology, respiratory, cardiovascular, and renal diseases, and they have several new drugs under development or regulatory registration that are expected to be released soon. One such revolutionary product is Vascepa® capsule, a single-molecule prescription containing icosapentaenoic acid